Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

The present invention relates to methods of assessing whether a patient has adenomyosis or is at risk of developing adenomyosis, to methods of selecting a patient for therapy of adenomyosis, and methods of monitoring a patient suffering from adenomyosis or being treated for adenomyosis, by determining the amount or concentration of sFRP4 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Methods, compositions, and systems are provided for detecting one or more a bacterial vaginosis issues by characterizing the microbiome of an individual, monitoring such effects, and/or determining, displaying, or promoting a therapy for the bacterial vaginosis issue. Methods, compositions, and systems are also provided for generating and comparing microbiome composition and/or functional diversity datasets. Methods, compositions, and systems are also provided for generating a characterization model and/or therapy model for bacterial vaginosis.

Disclosed is a menses cell capture device having at least one endometrial cell filter having a filter substrate defining a plurality of pores sized and arrayed so as to be effective in capturing endometrial cells, and a collection platform, such as a sanitary napkin or tampon, supporting said endometrial cell filters at least partially in the path of a menstrual flow in a configuration effective in collecting endometrial cells discharged in the menstrual flow.

Also disclosed is a method of screening for endometrial disorders in a subject by providing an endometrial cell filter at least partially positioned in a menstrual flow of said subject, recovering and identifying endometrial cells collected in the endometrial cell filter, and determining whether any of said endometrial cells present with an endometrial disorder, such as inter alia atypical hyperplasia and adenocarcinoma.

Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Disclosed are methods for diagnosing Bacterial Vaginosis (BV). The disclosed methods generally include detecting select species of Eggerthella and/or Prevotella, and optionally detecting select species of Lactobacillus. Also disclosed are nucleic acid oligomers and related compositions for detection of a 16S rRNA or its encoding gene from select species of Eggerthella, Prevotella, or Lactobacillus.

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

The present invention relates to methods of determining the clinical significance of an HPV infection in a subject and associated methods, systems and kits. The method involves detection of biomarkers associated with clinically significant HPV infections and associated dysplasia.

The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.

Methods of assessing obstetric outcomes of embryos based on the expression of alpha-fetoprotein (AFP), e.g., as measured in a biopsy from an embryo at the blastocyst stage, blastocoel fluid, or embryo culture conditioned media, such as blastocoel fluid conditioned media (BFCM), are provided.